149 related articles for article (PubMed ID: 38431109)
1. Dramatic increase in antimicrobial resistance in ESKAPE clinical isolates over the 2010-2020 decade in India.
Kharat AS; Makwana N; Nasser M; Gayen S; Yadav B; Kumar D; Veeraraghavan B; Mercier C
Int J Antimicrob Agents; 2024 May; 63(5):107125. PubMed ID: 38431109
[TBL] [Abstract][Full Text] [Related]
2. Plasmid profiles among some ESKAPE pathogens in a tertiary care centre in south India.
Ragupathi NKD; Bakthavatchalam YD; Mathur P; Pragasam AK; Walia K; Ohri VC; Veeraraghavan B
Indian J Med Res; 2019 Feb; 149(2):222-231. PubMed ID: 31219087
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial susceptibility of Gram-negative ESKAPE pathogens isolated from hospitalized patients with intra-abdominal and urinary tract infections in Asia-Pacific countries: SMART 2013-2015.
Karlowsky JA; Hoban DJ; Hackel MA; Lob SH; Sahm DF
J Med Microbiol; 2017 Jan; 66(1):61-69. PubMed ID: 28051952
[TBL] [Abstract][Full Text] [Related]
4. Update on the main MDR pathogens: prevalence and treatment options.
Esposito S; De Simone G
Infez Med; 2017 Dec; 25(4):301-310. PubMed ID: 29286008
[TBL] [Abstract][Full Text] [Related]
5. Functional Differences between E. coli and ESKAPE Pathogen GroES/GroEL.
Sivinski J; Ambrose AJ; Panfilenko I; Zerio CJ; Machulis JM; Mollasalehi N; Kaneko LK; Stevens M; Ray AM; Park Y; Wu C; Hoang QQ; Johnson SM; Chapman E
mBio; 2021 Jan; 12(1):. PubMed ID: 33436430
[TBL] [Abstract][Full Text] [Related]
6. Whole Genome Sequencing of Extended Spectrum β-lactamase (ESBL)-producing Klebsiella pneumoniae Isolated from Hospitalized Patients in KwaZulu-Natal, South Africa.
Founou RC; Founou LL; Allam M; Ismail A; Essack SY
Sci Rep; 2019 Apr; 9(1):6266. PubMed ID: 31000772
[TBL] [Abstract][Full Text] [Related]
7. Could chloramphenicol be used against ESKAPE pathogens? A review of in vitro data in the literature from the 21st century.
Čivljak R; Giannella M; Di Bella S; Petrosillo N
Expert Rev Anti Infect Ther; 2014 Feb; 12(2):249-64. PubMed ID: 24392752
[TBL] [Abstract][Full Text] [Related]
8. Structural Modification of Lipopolysaccharide Conferred by
Liu YY; Chandler CE; Leung LM; McElheny CL; Mettus RT; Shanks RMQ; Liu JH; Goodlett DR; Ernst RK; Doi Y
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28373195
[No Abstract] [Full Text] [Related]
9. Surveillance and comparison of antimicrobial susceptibility patterns of ESKAPE organisms isolated from patients with bacteraemia in South Africa, 2016 - 2017.
Ismail H; Lowman W; Govind CN; Swe Swe-Han K; Maloba MRB; Bamford C; Perovic O
S Afr Med J; 2019 Nov; 109(12):934-940. PubMed ID: 31865955
[TBL] [Abstract][Full Text] [Related]
10. Measurement and prediction of antimicrobial resistance in bloodstream infections by ESKAPE pathogens and Escherichia coli.
De Socio GV; Rubbioni P; Botta D; Cenci E; Belati A; Paggi R; Pasticci MB; Mencacci A
J Glob Antimicrob Resist; 2019 Dec; 19():154-160. PubMed ID: 31112804
[TBL] [Abstract][Full Text] [Related]
11. Differential anti-microbial secondary metabolites in different ESKAPE pathogens explain their adaptation in the hospital setup.
Tiwari V; Meena K; Tiwari M
Infect Genet Evol; 2018 Dec; 66():57-65. PubMed ID: 30227225
[TBL] [Abstract][Full Text] [Related]
12. In Vitro Emergence of High Persistence upon Periodic Aminoglycoside Challenge in the ESKAPE Pathogens.
Michiels JE; Van den Bergh B; Verstraeten N; Fauvart M; Michiels J
Antimicrob Agents Chemother; 2016 Aug; 60(8):4630-7. PubMed ID: 27185802
[TBL] [Abstract][Full Text] [Related]
13. Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.
Vrancianu CO; Gheorghe I; Dobre EG; Barbu IC; Cristian RE; Popa M; Lee SH; Limban C; Vlad IM; Chifiriuc MC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198306
[TBL] [Abstract][Full Text] [Related]
14. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
15. Alternatives for the treatment of infections caused by ESKAPE pathogens.
da Rosa TF; Coelho SS; Foletto VS; Bottega A; Serafin MB; Machado CS; Franco LN; de Paula BR; Hörner R
J Clin Pharm Ther; 2020 Aug; 45(4):863-873. PubMed ID: 32339305
[TBL] [Abstract][Full Text] [Related]
16. Update on antimicrobial susceptibility rates among gram-negative and gram-positive organisms in the United States: results from the Tigecycline Evaluation and Surveillance Trial (TEST) 2005 to 2007.
Dowzicky MJ; Park CH
Clin Ther; 2008 Nov; 30(11):2040-50. PubMed ID: 19108792
[TBL] [Abstract][Full Text] [Related]
17. Detection of ESKAPE Bacterial Pathogens at the Point of Care Using Isothermal DNA-Based Assays in a Portable Degas-Actuated Microfluidic Diagnostic Assay Platform.
Renner LD; Zan J; Hu LI; Martinez M; Resto PJ; Siegel AC; Torres C; Hall SB; Slezak TR; Nguyen TH; Weibel DB
Appl Environ Microbiol; 2017 Feb; 83(4):. PubMed ID: 27986722
[TBL] [Abstract][Full Text] [Related]
18. Characterisation of ESKAPE Pathogens with Special Reference to Multidrug Resistance and Biofilm Production in a Nepalese Hospital.
Pandey R; Mishra SK; Shrestha A
Infect Drug Resist; 2021; 14():2201-2212. PubMed ID: 34163185
[TBL] [Abstract][Full Text] [Related]
19. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
20. In Vitro Screening of an FDA-Approved Library Against ESKAPE Pathogens.
Younis W; AbdelKhalek A; Mayhoub AS; Seleem MN
Curr Pharm Des; 2017; 23(14):2147-2157. PubMed ID: 28190396
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]